Online inquiry

IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11966MR)

This product GTTS-WQ11966MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3&IGF1R gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005915.1; NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065; 3480
UniProt ID P21860; P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11966MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2914MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ10346MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ10329MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ8011MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ375MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 20D7S
GTTS-WQ731MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ8152MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HL036337
GTTS-WQ13781MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-1033
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW